FDA clears Orgovyx, the first-of-its-kind prostate cancer treatment.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Subject Terms:
      UNITED States. Food & Drug Administration
    • Abstract:
      The article reports that the Food & Drug Administration (FDA) has approved Relugolix also known as Orgovyx manufactured by Myovant Sciences for Prostate cancer treatment. Topics include that the therapeutic treatment works by blocking the pituitary gland from making luteinizing hormone and follicle-stimulating hormone and reduces the level of testosterone.